About

About Euthymics

Euthymics is a neuroscience-focused, clinical-stage biopharmaceutical company. Euthymics is developing a novel medicine for major depressive disorder. Euthymics’ management team is a group of experienced drug developers with a track record of success in neuroscience product development. We are dedicated to providing better medicines to patients with depression and alcohol use disorder.

 

The Euthymics team is led by co-founder Anthony McKinney and is joined by other seasoned drug developers. Members of the Euthymics team have been involved in the development of several successful neuroscience medications.

 

Euthymics Bioscience has been funded in a $28M series A venture capital investment by Novartis Venture Fund, Venture Investors, H&Q Healthcare Investors and H&Q Life Sciences Investors, GBS Venture Partners, State of Wisconsin Investment Board (SWIB) and Timothy J. Barberich.

 

 

Management team

 

anthony-mckinneyAnthony McKinney, M.B.A.

President & CEO, Co-Founder

 

Mr. McKinney began his career at Du Pont Merck with roles in hospital sales, market research and new product planning. He was part of the core team that launched Ethmozine, a class 1 anti-arrhythmic. He spent six years at Texas Biotechnology where he was closely involved in the development and approval of argatroban, a direct thrombin inhibitor. In 2000 Mr. McKinney was a member of the start-up executive team at Novazyme, a biotech involved in lysosomal storage disorders and which was subsequently acquired by Genzyme. At Genzyme he took on a Sr. VP and General Manager role and helped guide the integration of the Novazyme and Genzyme early phase research programs.

 

In 2004 Mr. McKinney began at Orexigen and in early 2005 became the Chief Operating Officer with involvement in all aspects of corporate fund raising including series B and C rounds, successful Initial Public Offering and follow-on secondary offering. He had primary oversight of a substantial IP portfolio resulting in 7 major patent allowances/issuances and was the co-inventor of several important patents underlying Contrave and Empatic formulations. Mr. McKinney also had direct responsibility of formulation development and manufacturing operations, Business Development, Corporate Communications, Reimbursement and Pricing Strategy and Biostatistics.

 

Mr. McKinney holds a Bachelor of Science in Microbiology (concentration in chemistry) from the University of Oklahoma and an M.B.A. in Global Management from the Thunderbird School of Global Management.

 

 

greg-beloffGregg Beloff

Acting Chief Financial Officer, Danforth Advisors

 

Gregg applies more than 20 years of experience in the life science and technology industries ranging from venture-backed start-ups to publicly traded companies. Gregg co-founded Danforth Advisors a firm providing C-level and related financing support to life science companies. In his role at Danforth he has served as the CFO of multiple companies including Seres Health, Moderna, Syros, Syndax and Yumanity. Previously, he served as the CFO of ImmunoGen and RXi, two publicly traded biotechnology companies and three privately biotechnology held companies, including Archemix. Prior to his CFO roles, Gregg was a life science investment banker with Adams, Harkness & Hill. He began his career as a corporate attorney with Gaffin & Krattenmaker, a Boston-based law firm. Gregg graduated with a B.A. from Middlebury College and then subsequently received his JD from the University of Pittsburgh School of Law and MBA from Carnegie Mellon University.

 

 

william-pappafotopoulosWilliam T. Pappafotopoulos, M.B.A.

Vice President, Finance and Administration

 

Mr. Pappafotopoulos has been President and CEO of the Milton Financial Group, which he founded in 1985 and which serves venture capital, bioscience and financial firms, among others. Prior to forming the Milton Financial Group, Mr. Pappafotopoulos held financial, accounting and management positions in Fortune 100 companies, including Johnson & Johnson and Raytheon, and in the government, at the Internal Revenue Service. Mr. Pappafotopoulos received a B.S. in Accounting from Salem State University and an M.B.A. from Suffolk University.

 

 

Board of Directors

 

Anthony McKinney, M.B.A.

Mr. McKinney began his career at Du Pont Merck with roles in hospital sales, market research and new product planning. He was part of the core team that launched Ethmozine, a class 1 anti-arrhythmic. He spent six years at Texas Biotechnology where he was closely involved in the development and approval of argatroban, a direct thrombin inhibitor. In 2000 Mr. McKinney was a member of the start-up executive team at Novazyme, a biotech involved in lysosomal storage disorders and which was subsequently acquired by Genzyme. At Genzyme he took on a Sr. VP and General Manager role and helped guide the integration of the Novazyme and Genzyme early phase research programs.

 

In 2004 Mr. McKinney began at Orexigen and in early 2005 became the Chief Operating Officer with involvement in all aspects of corporate fund raising including series B and C rounds, successful Initial Public Offering and follow-on secondary offering. He had primary oversight of a substantial IP portfolio resulting in 7 major patent allowances/issuances and was the co-inventor of several important patents underlying Contrave and Empatic formulations. Mr. McKinney also had direct responsibility of formulation development and manufacturing operations, Business Development, Corporate Communications, Reimbursement and Pricing Strategy and Biostatistics.

 

Mr. McKinney holds a Bachelor of Science in Microbiology (concentration in chemistry) from the University of Oklahoma and an M.B.A. in Global Management from the Thunderbird School of Global Management. Mr. McKinney also serves on the board of Neurovance, Inc.

 

Campbell Murray, M.D. (Chairman), Novartis Venture Fund

Dr. Murray has been Chairman of Euthymics since 2010 and is a Managing Director of the Novartis Venture Funds in Cambridge, MA, USA. Prior to joining the venture fund in 2005, he worked at the Novartis Institutes for BioMedical Research as the director of special projects reporting to the president & CEO. Dr. Murray is a New Zealand trained physician, Kauffman Fellow and holds an M.B.A. from Harvard Business School and an M.P.P. (public policy) from the John F. Kennedy School of Government where he was a Knox Fellow and Rotary Ambassadorial Scholar. Dr. Murray serves as a director on the boards of Aerpio Therapeutics, ­Alios BioPharm, Euthymics Biosciences, Galera, ImaginAB, Neurovance and Tokai Pharmaceuticals.

 

Paul Weiss, Ph.D., Venture Investors

Dr. Weiss has been a member of the Euthymics board since 2010. He joined Venture Investors in 2006 as a Managing Director, and focuses on making Healthcare investments. Dr. Weiss has over 20 years of operating experience in the biotech and pharmaceutical industries. He previously was President of the Gala Biotech business unit of Cardinal Health (now Catalent Pharma solutions). Before joining Gala, he served as the VP of Business Development for 3-Dimensional Pharmaceuticals, a biotechnology company that completed its IPO during his tenure, and was subsequently acquired by Johnson & Johnson. Earlier in his career, Dr. Weiss worked as Director of Licensing for Wyeth-Ayerst Pharmaceuticals, (now Pfizer). He also served as Director of Business Development and Research for Scientific Protein Labs, a division of American Home Products, and Director of Operations for Columbia Research Labs (Nasdaq: COB), a small, publicly held company that focuses on women’s health. Dr. Weiss is currently a member of the Boards of Directors for Aerpio Therapeutics, Akebia Therapeutics, Euthymics Bioscience, Mithridion, Neurovance, and ProCertus BioPharm (also acting President and CEO). He is an observer at Tissue Regeneration Systems and Inviragen. Dr. Weiss also serves on the Board of Directors for Tamir Biotechnology (formerly Alfacell Corporation, Nasdaq: ACEL). He received a B.S. in Biochemistry with honors from Carleton University-Ottawa, Ontario, a Ph.D. in Biochemistry and an M.B.A. from the University of Wisconsin-Madison, where he also worked as a postdoctoral research associate.

 

Daniel R. Omstead, Ph.D., Tekla Capital Management

Daniel R. Omstead, Ph.D., is President and Chief Executive Officer of Tekla Capital Management, LLC. He is also President of Tekla Healthcare Investors, Tekla Lifesciences Investors and Tekla Healthcare Opportunities Fund, three NYSE listed closed-end mutual funds that make venture and public equity investments principally in small, emerging healthcare-related companies. Prior to joining Tekla, Dan was President and CEO of Reprogenesis, Inc. a private development-stage biotech company developing therapies in the field of regenerative medicine. In 2000, Reprogenesis was merged with two other biotech companies to form Curis, Inc. Before joining Reprogenesis, Dr. Omstead was Senior Vice President, Research and Development at Cytotherapeutics, Inc a public biotech company that developed CNS therapies. Prior to entering the biotech industry, Dan was employed for fourteen years in the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both divisions of Johnson and Johnson and at Merck Sharpe and Dohme Research Laboratories, a division Merck and Company, Inc. While at J&J, Dan participated in the development of Orthoclone OKT3™, Eprex™/Procrit™ and other biological products. While at Merck, he worked on the development of Recombivax™, Mefoxin™, Heartguard™ and other traditional drug products. Dan holds Doctoral and Master’s Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University.

 

Brigitte Smith, M.B.A., GBS Venture Partners

Ms. Smith co-founded GBS Partners in 1997 where she serves as managing partner. She has twenty years’ experience in venture capital, business strategy and start-up company operations. Ms. Smith has been investing and managing investments for GBS’s $450 million of life science specialized venture capital funds for more than 17 years. She serves on the board of GBS portfolio companies AirXpanders Inc, Endoluminal Sciences Pty Ltd, Neuromonics Pty Ltd, Proacta Inc, Vivive Inc, and Neurovance/Euthymics. Ms. Smith was the founding investor and chair of Pharmaxis Pty Ltd. Prior to founding GBS, she worked in the US and Australia in operating roles with early stage technology based companies, and at Bain & Company as a strategic management consultant. Ms. Smith earned a B. Chem Eng (Honours) degree from the University of Melbourne, and as a Fulbright Scholar completed a MBA (Honours) from the Harvard Business School and a MALD from the Fletcher School of Law and Diplomacy, both in Boston, USA.

 

Timothy Barberich

Mr. Barberich joined the Euthymics board as an outside director in 2010. He is the founder and former president, chief executive officer and chairman of Sepracor Inc., a publicly traded pharmaceutical company based in Marlborough, Massachusetts which was acquired by Dainippon Sumitomo Pharma Co., Ltd. in 2009. He founded Sepracor in 1984 and was president and chief executive officer through 1999 when he also became chairman. He also serves on the boards of HeartWare, BioSphere Medical, Gemin X Biotechnologies and Resolyx Pharmaceuticals. Mr. Barberich also serves on the Neurovance board as an outside director. Prior to founding Sepracor, Mr. Barberich spent 10 years as a senior executive at Bedford, Massachusetts-based Millipore Corporation, a company that provides separations products to the life science research, pharmaceutical, biotechnology and electronic markets. Mr. Barberich is a graduate of Kings College. He holds a Bachelors of Science degree in Chemistry.